Delivra Health Brands (DHB) AI Stock Analysis

• Market Cap: C$6.25M
• Dividend Yield: N/A
• Average Volume (3M): 11.00K
• Price to Earnings (P/E): 181.8
• Beta (1Y): -0.60
• Revenue Growth: 4.04%
• EPS Growth: 80.24%
• Country: CA
• Employees: 22
• Sector: General
• Sector Strength: N/A
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 31,261,782
• 10 Day Avg. Volume: 14,027
• 30 Day Avg. Volume: 10,999
• PEG Ratio: -63.46
• Price to Book (P/B): 13.25
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 14.59
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$0.72
• Price Target Upside: 260.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 70 Neutral
• Price Target: C$0.50 ▲(150.00%Upside)

Delivra Health Brands is on a positive trajectory with strong corporate events and technical indicators. Financial performance shows promising revenue growth but is hindered by profitability issues. The high-risk valuation due to negative earnings is offset by strategic market expansions and product launches.

Delivra Health Brands Business Overview & Revenue Model

Company Description

Delivra Health Brands Inc. through its subsidiaries, provides lifestyle and wellness products to consumers and patients in regulated markets worldwide. The company is involved in selling of cannabis, liquid sleep shots, sleep powder packets, gummies, and pain relief creams. It offers its products under LivRelief, Dream Water, and LivRelief infused brand names. The company was formerly known as Harvest One Cannabis Inc. Delivra Health Brands Inc. is headquartered in Vancouver, Canada.

How the Company Makes Money

Delivra Health Brands generates revenue primarily through the sale of its proprietary topical and transdermal products. The company markets these products directly to consumers as well as through partnerships with retailers and distributors in the health and wellness industry. In addition to direct product sales, DHB may also engage in licensing agreements, allowing other companies to utilize its patented delivery technologies in their own product lines. Significant partnerships with healthcare providers or retail chains can amplify distribution and sales, further contributing to the company's earnings. Additionally, the company may invest in research and development to continue innovating and expanding its product offerings, which can lead to new revenue streams.

Delivra Health Brands Financial Statement Overview

Summary

Delivra Health Brands is on a recovery path with improving revenue and gross profit margins. However, persistent negative EBIT margins and low net profitability remain concerns. The balance sheet is stable, with manageable debt levels and decent equity ratios. Cash flow improvements are a positive sign, indicating better operational efficiency.

Income Statement

Delivra Health Brands has shown positive trends in revenue growth, with an increase from $9.79M in 2023 to $12.57M in TTM, resulting in a 28.4% growth rate. The gross profit margin has improved significantly to 47.2% in TTM, indicating better cost management. However, the company is struggling with negative EBIT margins and thin net profit margins, which could be a concern for long-term profitability.

Balance Sheet

The balance sheet shows a relatively stable equity base with a debt-to-equity ratio of 0.50 in TTM, indicating modest leverage. The equity ratio stands at 50.9%, showing solid equity financing. However, the return on equity is minimal at 0.14%, reflecting the challenge in generating returns from equity capital.

Cash Flow

The cash flow statement highlights a positive trend in free cash flow, which increased from negative values to $407K in TTM. The operating cash flow to net income ratio is high, indicating strong cash generation relative to reported profits. The company needs to maintain this momentum to ensure liquidity and operational flexibility.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
12.57M	12.38M	9.79M	8.14M	7.96M	7.78M
	Gross Profit
5.94M	6.40M	3.49M	485.00K	-297.00K	-1.62M
	EBIT
-1.14M	-710.00K	-1.36M	-6.01M	-9.26M	-15.69M
	EBITDA
1.58M	2.35M	1.40M	-4.25M	-7.04M	-55.40M
	Net Income Common Stockholders
6.00K	876.00K	-184.00K	-7.01M	-28.54M	-79.86M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
3.85M	4.20M	2.73M	1.11M	5.14M	1.41M
	Total Assets
8.46M	10.05M	10.56M	11.59M	19.06M	57.84M
	Total Debt
2.15M	2.03M	1.96M	2.11M	2.16M	5.97M
	Net Debt
-1.70M	-2.17M	-764.00K	1.02M	-2.27M	4.57M
	Total Liabilities
4.15M	4.86M	7.17M	8.21M	9.09M	21.27M
	Stockholders Equity
4.31M	5.19M	3.39M	3.37M	9.98M	33.52M
Cash Flow		Free Cash Flow
407.00K	756.00K	-1.13M	-4.46M	-9.68M	-24.67M
	Operating Cash Flow
407.00K	756.00K	-1.09M	-4.44M	-9.65M	-18.36M
	Investing Cash Flow
0.00	11.00K	2.91M	1.35M	12.27M	-3.64M
	Financing Cash Flow
-140.00K	594.00K	-255.00K	-309.00K	446.00K	3.17M

Delivra Health Brands Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DHB, the sentiment is Neutral. The current price of 0.2 is below the 20-day moving average (MA) of 0.21, above the 50-day MA of 0.19, and above the 200-day MA of 0.20, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 48.28 is Neutral, neither overbought nor oversold. The STOCH value of 29.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:DHB.

Delivra Health Brands Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DHB	70 Neutral	C$6.25M	181.82	-3.45%	―	4.04%	80.24%
Sector *	58 Neutral	$4.93B	19.81	-16.90%	5.28%	13.61%	-24.47%
WLLW	46 Neutral	C$4.42M	―	-971.43%	―	571.23%	64.24%
BBRRF		$5.42M	―	-112.06%	―	―	―
NDVAF		$4.29M	―		―	―	―
IMCC		$8.49M	―	-63.75%	―	―	―
CANB	53 Neutral	C$6.91M	30.00	2.43%	―	-14.41%	-93.67%

Delivra Health Brands Corporate Events

Delivra Health Expands U.S. Reach Through QVC Partnership

Delivra Health Brands has expanded its U.S. presence by partnering with QVC, a major televised and online shopping network. This collaboration will enhance the distribution and visibility of its Dream Water Snoozeberry Sleep Shots, potentially increasing brand loyalty and consumer engagement through QVC’s unique shopping experience.

The most recent analyst rating on (TSE:DHB) stock is a Buy with a C$0.09 price target. To see the full list of analyst forecasts on Delivra Health Brands stock, see the TSE:DHB Stock Forecast page.

Delivra Health Brands Enhances Investor Relations with New Partnerships

Delivra Health Brands Inc. has engaged Global One Media and Bergskogar Limited for investor relations services to enhance its digital marketing and global business development efforts. These collaborations are expected to strengthen Delivra Health’s market presence and visibility, potentially impacting its operations and stakeholder interests positively.

The most recent analyst rating on (TSE:DHB) stock is a Buy with a C$0.09 price target. To see the full list of analyst forecasts on Delivra Health Brands stock, see the TSE:DHB Stock Forecast page.

Delivra Health Achieves Positive Q3 EBITDA Amid Strategic Marketing Push

Delivra Health Brands reported a positive adjusted EBITDA for the third quarter of fiscal 2025, driven by strong marketing momentum and growth in units sold. The company achieved a 3% year-over-year revenue increase and expanded its Dream Water product offerings in Canada, while also launching successful marketing campaigns for its LivRelief brand. Despite a reduction in gross profit margin due to higher costs, Delivra Health’s strategic investments in marketing and product innovation have laid a strong foundation for future growth.

The most recent analyst rating on (TSE:DHB) stock is a Buy with a C$0.09 price target. To see the full list of analyst forecasts on Delivra Health Brands stock, see the TSE:DHB Stock Forecast page.

Delivra Health Expands Dream Water® Brand with New Product Launch in Middle East

Delivra Health Brands Inc. is expanding its Dream Water® product line by launching 60-Count Sleep Gummies in the Middle Eastern markets through its Kuwait-based distributor. This strategic move is expected to enhance the brand’s presence and growth in new markets, leveraging the success of its sleep solutions in Canada and the U.S., and offering more choices to consumers in the region.

Delivra Health Expands Dream Water® Line with New Sleep Gummies in Canada

Delivra Health Brands has announced the launch of its new 6-Count Sleep Gummies under the Dream Water® brand in the Canadian market, following the success of its 60-count version. This strategic launch aims to capture growth opportunities in travel and convenience retail channels, enhancing the company’s market position as a leading provider of sleep solutions. The new product will be distributed nationwide through established retail and e-commerce partners, potentially strengthening Delivra Health’s presence in both Canadian and US markets.